Stereotactic Body Radiotherapy for Metachronous Multisite Oligo-Recurrence: A Long-Surviving Case with Sequential Oligo-Recurrence in Four Different Organs Treated Using Locally Radical Radiotherapy and a Review of the Literature

Table 3

Reports of stereotactic body radiotherapy for isolated abdominal lymph node metastases.

Authors	Study design	Number of patients	Primary organ	Dose/fractionation	Followup (months)	Outcomes	Toxicity
McCammon et al. [48]	Retrospective	30	Uterine cervix: 28; Uterine corpus: 2	30–45 Gy/3 fr; (covering PTV); (+EBRT 27–45 Gy)	2–65 (median; 16)	4-year OS: 50.1%; 4-year LC: 67.4	No severe complication on intestine
Onishi et al. [49]	Retrospective	7	Stomach: 7	45–51 Gy/3 fr; (covering PTV)	19–33 (median: 26)	CR: 5/7, PR: 2/7; 3-year OS, PFS: 43%, 29%	No severe complication
Choi et al. [50]	Retrospective	7	Colorectal: 7	36–51 Gy/3 fr; (covering PTV)	15–70 (median; 26)	1-, 3-year OS: 100%, 71.4%; MS: 37 months,	Grade 4 intestine: 1

Abbreviations: LC: local control rate; MS: median survival time; OS: overall survival rate; CR: complete remission; PR: partial remission; PFS: progression free survival.